Study of a new drug for myelofibrosis and polycythemia vera
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have polycythemia vera (PV) or myelofibrosis (MF), confirmed by a doctor
- You have a specific gene change called JAK2 V617
- You are generally able to take care of yourself (ECOG score 0-1)
- You have adequate liver, kidney, and bone marrow function
- If female, you are not pregnant or breastfeeding and agree to use contraception
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral drug (ZE74-0282) for people with blood cancers that have a specific genetic change called JAK2 V617F. The goal is to see if the drug is safe and helps control the cancer.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This trial tests a new drug called revumenib, which is being studied for people with myelofibrosis. Revumenib may help slow the disease and improve symptoms. The study has two parts: one for people who have already tried a JAK inhibitor, and one for those currently on a JAK inhibitor but still have active disease.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
This study follows people with myelofibrosis and anemia who are starting a new treatment. It aims to learn more about the disease and how treatments work in real life.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.